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ABSTRACT  Psoriasis was used as a model to analyze the pathogenetic pathways of immune-mediated inflammatory diseases, and the results of bioinformatic, 
molecular-genetic and proteomic studies are provided. cell mechanisms, common for the pathogenesis of psoriasis, as well as crohn’s disease, are identified. new 
approaches for immune-mediated diseases are discussed. 
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INTRODuCTION:
Psoriasis (Psoriasis vulgaris, OMMIM 177900) is a chronic in-
flammatory, recurring, immune-mediated skin disease that 
involves several other organs and systems. Psoriasis is a com-
plicated genetically based pathology, which involves several 
groups of genes [1].
the most common clinical manifestations of psoriasis are 
the appearance of dry, red patches of skin covered with sil-
very scales. the affected skin is characterized by an increase 
of the skin cell number and consequent inflammation due to 
the abnormal keratinocyte differentiation and infiltration of 
antigen-presenting cells, activation of t-helper cells, and re-
lease of proinflammatory cytokines [1, 2]. the appearance of 
“unaffected” or “uninvolved” skin is normal. However, the 
gene expression profiling shows that major changes happen 
in both damaged and undamaged skin of a psoriatic patient, 
as compared with the skin of a healthy individual [3].
It is supposed that the multi-gene nature of this disease 
is associated with the presence of several locuses, related to 
the susceptibility to the disease, known as PSOrS1-PSOrS9 
(Psoriasis Susceptibility) and located on at least 9 chromo-
somes. Within these chromosomal regions several genes are 
mapped  candidates to be involved in this pathological proc-
ess [4-6]. In addition, the development of psoriasis may be 
influenced by several other genomic locuses [7-9]. Accord-
ing to the data appeared in 2008, candidate genes involved in 
the development of psoriasis may be located on 10 different 
locuses (PSOrS1-PSOrS10) [10].  A strong genetic basis  of 
this disease has been confirmed by family and twin studies 
that show a high percentage of inheritance (up to 80%), as 
well as  higher concordance (about 70%) in monozygotic twins 
than in dizygotic twins (up to 30%) [8]. However, just like any 
other multifactorial diseases, psoriasis is influenced not only 
by genetic factors, but also by the environment.  Many en-
vironmental factors may play a role in the development of 
this disease in susceptible individuals: a mechanical damage 
skin that may lead to the Kebner’s effect (development of 
psoriatic lesions on the site of epidermal trauma), surgical 
intervention, uV-radiation, high body mass index, excessive 
alcohol consumption and smoking, stress factors, including 
physiological, psycho-emotional and cold stressors[6].
It is well known that bacterial, fungal and virus infections 
can influence the development of psoriasis [11, 12].  Drugs, 
such as β –blockers [13], angiotensin-converting enzyme in-
hibitors [14], antimalarial drugs [15], and lithium [16] can also 
trigger the development of the disease.  Studies show that 
psycho-emotional stresses can provoke psoriasis development 
in 23% of the patients, medication - in 16%, physical trauma 
- in 43%, and infections (over all) - in 14% [17]. the other 4%, 
perhaps, include other triggering agents. 
therefore, the main reason behind the appearance of pso-
riasis is unknown; however, it is obvious that this disease is 
a result of the combined influence of several genetic and en-
vironmental factors, as well as the patient’s lifestyle.  Gene 
profiling studies show that psoriasis is an immune–mediated 
inflammatory disease, where epidermal cell structure disbal-126 | ActA nAturAe |  № 3 2009
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ance , as well as abnormal cell growth and differentiation, is 
the result of molecular stress signals that initiate an improper 
immune response [3]. 
A study of the molecular mechanisms of the  development 
of psoriasis was performed on the clinical, bioinformatical, 
molecular-genetic, and proteomic levels.  the ethnic back-
grounds of psoriasis patients were taken into consideration, 
and comparison with the development of other diseases (spe-
cifically crohn’s disease and atherosclerosis) was performed. 
MATERIALS AND METHODS
Skin samples collection from psoriatic patients was done un-
der local anesthetic with the use of dermatological biopsy 
punch (4mm). Patients received no systematic PuVA/uV 
therapy for a month before the skin biopsy (table 1). Biopsy 
samples from unaffected skin regions were taken at a dis-
tance of 3 cm from the damaged skin region [3, 18, 19].  the 
study was approved by the local ethic committee at the Ge-
netics Institute of the russian Academy of Sciences (rAS) 
and was conducted in agreement with the principles of the 
Declaration of Helsinki. 
to grade the severity of psoriasis, a Psoriasis Area and Se-
verity Index (PASI) were used.  to calculate overall PASI, 
local PASI for different body parts were first obtained, using 
the following formula: PASI = fraction x area x (redness x 
peeling x thickness).  Over all, PASI is equal to the sum of lo-
cal PASI and can differ in range from 0 to 72. Maximum PASI 
in this study group was 11.4; minimal, 1.8, meaning that all 
the patients had an acute form of the disease. the presence or 
absence of psoriatic arthritis accompanying psoriasis is show 
in column PsA (table 1).
collection of atherosclerosis’ autopsies was done from 
postmortem material.   to achieve that, the abdominal aorta 
with signs of atherosclerosis was taken and samples from the 
tunica intima layer of atheromatous plaques were collected. 
Autopsies from the healthy part of the aorta were collected in 
the same manner. Samples were collected from patients who 
were treated for different diseases (table 2).
RNA extraction from biopsies was done by the Qiagen Kit 
protocol. rnA was cleaned from DnA contamination using 
DnAse Qiagen®.
Reverse transcription was done using Promega’s reverse 
transcriptase M-MLV protocol.
Real-time PCR was done using the fluorescent-labelled 
oligonucleotide probes. reaction was done using the chemical 
supplies manufactured by the company eurogene. All of the 
primers and probes were synthesized by the DnA-Syntez 
company. GAPDH was taken as a control for the target genes 
expression. results analysis was done using Pcr reactions 
with the following conditions: reaction  efficiency more than 
95%, correlation coefficient no less then 0.99, and slope -3.4  ± 
0.2. Method 2-ΔΔct was used to analyze the results of polymer-
ase chain reaction, according to [20]. 
to study the proteomic profiles, samples of damaged and 
visually undamaged skin were used. Proteins were extracted 
and studied using two-dimensional electrophoresis. A silver 
dye was used to visualize the gel lines. the images obtained 
were analyzed using the Melanie II program (GeneBio, Swit-
zerland). Protein identification was done using the methods 
Table 1. Patient`s information
Gender Age Psoriasis 
type PASI PsA Inheritance
1 M 22 P. vulgaris 4.0 no Denies
2 M 36 P. vulgaris 7.2 no Father has psoriasis
3 M 23 P. vulgaris 1.8 no Father and brother 
have psoriasis
4 M 51 P. vulgaris 9.4 no Mother has psoriasis
5 M 38 P. vulgaris 2.1 no Denies
6 M 57 P. vulgaris 4.2 no Father has psoriasis
7 M 51 P. vulgaris 2.1 no Denies
8 M 40 P. vulgaris 2.8 no Father has psoriasis
9 M 34 P. vulgaris 3.2 no Mother has psoriasis
10 M 49 P. vulgaris 11.4 no Denies
Table 2. Pathological diagnosis of patients with atherosclerosis
Patient Age Gender Diagnosis
1 80 F encephalopathy. Brain atrophy, internal hydrocephalis. Arthrosclerosis of brain arteries. type II Diabetes. Sclerosis, pancreatic 
lipomatosis.
2 70 F Ischemic infraction of right-frontal lobe. Arthrosclerosis of the brain vessels with stenosis up to 50%. type II Diabetes. 
Hypertension. Arthrosclerosis of heart blood vessels with stenosis up to 75%.
3 77 M Infraction of the brain in the area of the middle brain artery. type II Diabetes. Hypertension III degree. Ischemic hear disease: 
atherosclerotic cardiosclerosis. 
4 67 F
chronic stomach ulcers. chronic intestinal ulcers. Diffuse cardiosclerosis. Postmyocardial infraction cardiosclerosis. 
Arthrosclerosis of the coronary blood vessels with stenosis of 70%. type II Diabetes. Arthrosclerosis of brain vessels with 
stenosis of 30%.
5 75 F
Breast cancer. Phlebothrombosis in the right crus. Pulmonary thromboembolism of lung artery. encephalopathy. Arthrosclerosis 
of brain vessels with stenosis of 25%. chronic obstructive bronchitis, diffuse pneumosclerosis, obstructive pulmonary 
emphysema. Gastritis.
6 80 M Large postmyocardial infraction cardiosclerosis. Arthrosclerosis of the coronary blood vessels with stenosis of 75%. Secondary 
hypertensison. Bilateral nephrosclerosis. chronic renal insufficiency.
7 64 M chronic alcoholic intoxication. Bilateral bronchial pneumonia. Ischemic heart disease: arthrosclerosis of the coronary blood 
vessels with stenosis of 40%.
8 87 M Large postmyocardial infraction cardiosclerosis. Arthrosclerosis of the coronary blood vessels with stenosis of 50%. Hypertension 
of the small blood-circulation circle. Arthrosclerosis of the brain vessels with stenosis of 30-50%.reSeArcH ArtIcLeS
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of MALDI-tOF mass-spectrometry and nano Lc-MS/MS 
mass-spectrometry at the Proteomic center of the Institute 
of Biomedical chemistry of the russian Academy of Medical 
Sciences (rAMS). 
the GeO DataSets (http://www.ncbi.nlm.nih.gov/geo/) 
database was used to for bioinformatics analysis.  the GeO 
DataSets database contains a number of electronic tables 
where the gene expression microarray results are collected. 
the Metacore® program produced by GeneGo Inc (uSA) was 
used for the analysis. the Metacore® program established 
that the lowest p-value correlates to the higher possibility of 
gene involvement into the process.  the original threshold for 
the p-value was established as equal to 0.05. 
RESuLTS AND DISCuSSION:
THE ROLE OF ETHNIC BACKGROuND IN 
THE DEVELOPMENT OF PSORIASIS 
During the last several decades, extensive knowledge has 
been collected showing that in addition to individual differ-
ences in the metabolism of medical compounds and system 
reactions to those compounds, as related to their therapeutic 
and side effects, there are also individual differences in peo-
ple’s susceptibility to diseases. the investigation of the fac-
tors that influence an individual’s susceptibility to a specific 
disease and a patient’s response to treatment was started in 
the 1970s under the leadership of L.A. Piruzyan [21, 22].  the 
necessity of tracking the kinetics of metabolic changes during 
the process of chemical compound interaction with biological 
objects was stressed [23].
One’s ethnic background also plays a very important role 
in the development of complicated diseases, such as psoria-
sis.  On average, 2-3% of the world’s population suffers from 
psoriasis. However, these data vary considerably depending 
on the country, geographic region, and ethnic background 
of the patient [24].  there is a huge geographic variation in 
the occurrence of psoriasis (Figure 1) [25]. the huge differ-
ence in the disease’s incidence between Asia and europe is 
proof of the significance of the ethnic component in the de-
velopment of psoriasis. It is obvious that a regional-ethnic 
differentiation in the occurrence of psoriasis exists [7, 8, 26].   
However, data on the occurrence of psoriasis collected in dif-
ferent populations is somewhat contradictory, which could 
mean that different analytical methods were used in the col-
lection of the data. In order to make data collection easier and 
to standardize the analytical methods, we developed an Indi-
vidual Information card (IIc), which includes more than 50 
grading profiles [27, 28]. the analysis of the genetic structures 
of samples from Dagestan by the IIc method, as well as fam-
ily pedigrees, showed high ethnic purity, which is a result of 
very few marriages across ethnic groups. the consequence of 
this is a high level of endogamy, which leads to a rise in the 
degree of homozygosis in the population. Besides, the study 
of the genealogical trees includes a large number of fami-
lies with multiple children, which provides an easier way of 
tracking families’ structures in the space of 3-4 generations. 
For example, the average number of children in the families 
of Avarecs, Dagestanis, Lezgins, Lakcevs, Azerbaijanis, and 
nogaicis is 3; the average number of children in the families 
of Kalmyks, tabasarans, and Agul’s is 4; but in russian fami-
lies the average number of children is only 1. It should also 
be noted that in such families several generations live fairly 
close to each other and, therefore, are influenced by similar 
environmental factors. 
Our study showed a significant difference in the presence 
of complications and duration of the disease depending on the 
type of illness (type I – early, type II – late) in the different 
ethnic groups of Dagestan.  the data obtained in this study 
show the important role of the ethnic component in the inher-
itance of such a complicated pathology as psoriasis. the data 
also show that it is possible to use IIc and a model population 
from Dagestan to study the type of psoriasis’ inheritance with 
reference to the ethnic component [29].
A psoriasis sensitivity gene study done on samples obtained 
from russian, tatarstan, Bashkortostan, and Hakasiyan eth-
nic groups in the republics of Bashkortostan and Hakasiya 
showed that the polymorphic gene locuses HLA-c and Hcr 
are the basic sensitivity markers for psoriasis in the analyzed 
regions, regardless of the form of the disease and the ethnic 
group [30]. 
In order to study the incidence of psoriasis and for gene 
expression profiling, it is necessary to align all the data ac-
cording to all the parameters of the study. Several differences 
in gene expression using Affimetrix-chips in Japanese pa-
tients with psoriasis and the results obtained with a similar 
method in four other study groups show variability in gene 
expression in individual patients based on age, gender, and 
environmental factors [3, 31, 32, 33, 34].
ANALySIS OF BIOLOGICAL MICROARRAyS
today, the use of methods that allow to systematize and 
compress a vast pool of genetic information is widespread. 
this allows to explain different gene interactions. One such 
method is Metacore®, a program built by GeneGo Inc. (uSA).   
As a result of gene expression microarray analysis of at least 
12,000 genes using Metacore®, we concluded that 7,563 genes 
changed expression at least 1.5 times [35]. Figure 2 contains 
the list of processes changed in psoriasis-.  the main proc-
esses that change under the influence of psoriasis are the im-
mune response, cell cycle, inflammatory response, prolifera-
tion, and others. the process of disease development involves 
a number of immune system cells, such as t-lymphocytes 
(th1, th17), antigen-presenting cells (APc) – dendrite cells, 
Langerhans cells, macrophages., and natural killer (nK) cells 
Fig. 1. Frequency distribution of psoriasis case rates in different regions 
of the world. The percentage of case rates in Aborigines is marked in 
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[36]. cell-to-cell signaling is done with the help of signaling 
molecules – cytokines, as well as by the interactions of vari-
ous cell receptors with their ligands.  For example, receptors 
tLr (toll-like receptors) belong to the family of receptors 
that promote an immune response when a viral or microbial 
presence is detected. these receptors are expressed not only 
on the surface of immune system cells (monocytes, macro-
phages, dendrite cells, and granulocytes), but also on the sur-
face of the epithelial cells in the respiratory tract and the skin 
– important regions of host - pathogen interaction [37]. the 
tLr family includes 11 receptors, and its ligands include li-
popolysaccharides, single-stranded or double-stranded rnA, 
lipoproteins, flagellin, and unmethylated DnA [38]. Stimu-
lation of these receptors results in stimulation of an entire 
complex of signaling cascades, including nF-kappaB/rel, 
IrF and MAPK – erK, JnK, and p38. For example, MAPK 
induces the expression of AP-1 family transcription factors, 
such as Fos and Jun, and activates transcription activity in 
the protein complex AP-1, starting several processes lead-
ing to inflammation [39]. As a result, the expression of anti-
inflammatory cytokines (IL-6, IFn- γ, IL-12 and tnF- α) in 
both induced and co-stimulating molecules, such as cD80 and 
Fig. 2. Forty most altered processes (from the most altered to the less altered) in psoriatic skin compared to the skin of healthy volunteers (A) and 
twenty most altered processes (from the most altered to the less altered) in psoriatic lesions compared to the unaffected skin (B)
1.  Cell cycle regulation
2. Immune response, phagosomes 
3. Antigen presentation
4. Neutrophil activation
5. Inflammation, JAC – STAT pathway
6. Inflammation, amphoterin
7. DNA damage control
8. Positive regulation of cell division
9. Cell cycle regulation, interleukin
10. Negative regulation of cell division
11. Cell adhesion, integrin
12. Inflammation, NK-cells
13. Inflammation, interferon role
14. Phagocytosis
15. Inflammation, IL-4 role
16. Cytoskeleton regulation
17. TNF- β signaling pathway
18. Cell cycle, G2-M bridge
19. Histamine’s role in inflammation
20. Cell adhesion, leucocytes participation
21. Cell adhesion, chemotaxis
22. Translation initiation regulation
23. Anti-inflammatory action of IL-10
24. Apoptosis regulation
25. IFN-γ participation in inflammation
26. TREM1 participation in inflammation
27. MIF participation in inflammation
28. Angiogenesis
29. Cell cycle, S-phase
30. Inflammation, role of IL-2
31. Lymphocytes proliferation
32. Chemotaxis
33. Inflammation, Protein C participation
34. Stimulation of apoptosis by external factors
35. Inflammation, the role of IL-6
36. Development of bone tissue
37. The role of cell receptors in cell adhesion
38. Cell cycle, mitosis
39. Inflammation, the role of IgE
40. Cell adhesion, thrombocytes aggregation
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cD86, activates the immune response [40, 41]. considering 
that viruses and bacteria are the main triggers of psoriasis, 
these receptors play an important role in the initiation of the 
disease [38, 42]. 
In the entire family of chemokines, a high level of expres-
sion was noticed in ccr4, ccr5, ccr6, ccr10, and cXcr3. 
chemokines belong to the group of anti-inflammatory cy-
tokines and provoke an influx of th1 cells into the inflamed 
regions [43]. expression of receptors ccr4 and ccr10 usu-
ally occurs in cD4+ and cD8+ memory t-cells with cLA + 
phenotype (cutaneous lymphocyte antigen), which decides 
on the lymphocyte migration into the lymphatic nodes [44]. 
A ligand for the receptor ccr4 is ccL17, which is expressed 
on the endothelial surface of dermal blood vessels, along with 
ligand ccL27, and provokes the migration of leucocytes into 
the skin [45]. An expression level of ligand ccL27, which is a 
ligand for receptor ccr10, occurs in keratinocytes under the 
influence of anti-inflammatory cytokines IL-1 and tnF- α. 
In this way, interaction of ccr10-ccL27 involves t-cells in 
the inflammatory process in the skin [46]. cXcL16 in athero-
sclerosis can be used as an example of the regulation mecha-
nism of chemokine expression. expression of this chemokine 
is induced via IL-18 through the following signaling path-
way: MyD88 → IrAK1-IrAK4-trAF6 (tumor necrosis factor 
receptor – associated factor 6) → c-Src → PI3K → AKt→ JnK 
→ AP-1 [47].  
Data shows that the transcription factor AP-1 acts as a 
common link of the regulatory pathways of tLr-receptors 
and chemokines.
ANALySIS OF GENE-TO-GENE INTERACTIONS IN PSORIASIS 
Signal transmission from eFG (epidermal Growth Factor) 
receptor inside the cell, shown in figures 3a and 3b, can be 
used as an example of gene-to-gene interaction in psoriasis. 
Both figures show that genes coding transcription factors, 
such as c-Fos, c-Myc, c-Jun and eLK1, are activated via sig-
nal transmission from eGFr through GrB2 and Shc to SOS, 
and then through the following pathway: h-ras → c-rAF → 
MeK1/2 → erK1/2 → transcription factors. regardless of the 
fact that the expression levels is changed only for some genes 
coding corresponding mediator signals (GrB2, Shc, SOS, h-
ras, c-rAF, MeK1/2), like, for example c-rAF (Figure 3a), 
expression of transcription factor c-Fos, c-Myc, c-Jun, eLK1, 
and StAt3 turned out to be a lot higher in cases of damaged 
skin than in the undamaged skin of psoriatic patients, and 
higher than in the skin of healthy volunteers [35]. 
Figure 4 shows the degree of change in the eGF gene sig-
naling pathway expression in the skin of psoriatic patients. 
We compared the threshold change (Fold change) of gene 
expression in psoriasis lesions as compared to the normal skin 
(Figure 4a) and phenotypically healthy skin of some patients. 
Fold change (Fc) of expression was established as 2. Figures 
4a and 4b show some protein-to-protein interactions that 
are the part of signaling pathways induced by the epider-
mal Growth Factor (ePF) and its ligands. Green arrows show 
consecutive activation of protein interaction either through 
bounding or phosphorylation. It is noticeable that the expres-
sion of some eGFr-ligands is higher in the psoriasis-damaged 
skin (HB-eGF and amphiregulin – expression increased 5.77 
and 4.96 times, accordingly). Figure 4a shows that each gene 
а
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Fig. 3. Signal transduction pathway from EGF to AP-1 and alteration of 
expression of some genes responsible for this process during psoriasis in 
skin (A – skin of psoriatic patients compared to the skin of healthy vol-
unteers, B – in affected skin compared to the unaffected skin of psoriatic 
patients, C – the notation conventions). There are also designations 
used on the maps that characterize the  alteration of the level of expres-
sion of genes: - downregulation ;  upregulation130 | ActA nAturAe |  № 3 2009
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coding the proteins of the signaling pathway is upregulated; 
for example, c-raf kinase with Fc = 4.46 and c-Src with Fc = 
3.96. Moreover, transcription factors themselves are upregu-
lated as well. therefore, the expression of c-Myc is increased 
6 and 15 times; c-Jun, 3.35 times; StAt1, 17 times; and c-
Jun, 34 times. the general picture of gene expression changes 
is shown in Figure 4b. StAt3 is upregulated 8.6 times. this 
leads to the conclusion that the cells involved in this patho-
logical process are characterized by a significant change in 
the levels of gene expression, involving a significant number 
of various molecular pathways and their associated transcrip-
tion factors in this complicated process. A close look needs to 
be taken at the overexpression of those transcription factors, 
since under normal conditions these transcription factors do 
not show such sudden changes in the expression levels. the 
uninvolved – meaning visually healthy – skin of psoriatic 
patients is somewhere in between the skin of the healthy in-
dividual and the inflamed skin of the patient, since the dif-
ference between samples collected from the visually healthy 
skin of a psoriatic patient and damaged skin is significant, but 
not as significant as the difference between the damaged skin 
of a patient and the skin of a healthy individual. 
After the analysis of gene interactions, we concluded that 
in all of the processes studied the main transcription factors 
that changed their expression in psoriasis, only components of 
transcription factor AP-1 and transcription factor nF-kB are 
present. transcription factor nF-kB is activated during the 
immune response. In this particular study, we analyzed  the 
role of components of transcription factor AP-1 [48].
TRANSCRIPTION ANALySIS
Our group had a significant interest in the comparison of the 
level expression of genes in the damaged skin regions of psori-
atic patients as compared to the expression of the same genes 
in the visually unaffected skin regions located no farther than 
3cm from the affected regions. this kind of comparison was 
done in several other laboratories around the world [3, 18, 
19], and it allows for maximum purity of the experiment. A 
threshold of change of the expression levels was established 
for each of the genes equal to 2. Based on a search of the lit-
erature and several databases, we established a number of 
genes that may be important for experimental study. these 
genes include genes that code transcription factor AP-1 (C-
JUN, JUNB, JUND, C-FOS, FOSB, FRA-1, FRA-2, and oth-
ers). 
using a real-time polymerase chain reaction, we were able 
to analyze the levels of gene expression for 12 genes in the 
damaged skin and compare it with the visually unaffected 
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Fig. 4. Level of expression alteration of EGF signal transduction pathway genes in the skin of psoriatic patients: A- as compared to the skin of healthy 
individuals, B- in affected skin compared to the phenotypically normal skin of the same patients, В - the notation conventions. The hue of the color 
depends on the absolute value of the expression change (the bigger the change, the more saturated the color)reSeArcH ArtIcLeS
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skin of the same psoriatic patient (data not shown). results of 
this experiment showed that practically all patients showed a 
more than doubled expression of gene FRA-1 in the damaged 
skin compared to the visually unaffected skin regions (Figure 
5). All other genes differed in the direction of change of their 
expression.
For comparison, we were able to analyze the expression 
levels of gene FRA-1 in the samples obtained from the athero-
sclerotic patients. 
results obtained with real-time Pcr showed an increase in 
the expression of gene FRA-1 in all patients in the atheroscle-
rosis-affected region of the blood vessels and those suffering 
from skin psoriasis (Figure 6).  At the same time, pathological 
activation of FRA-1 expression, as a component of AP-1, can 
lead to an increase in IL-2 expression and the consequential 
stimulation of auto-reactive cytotoxic t-lymphocytes, fol-
lowed by an increase in the production of anti-inflammatory 
cytokines and autoantibodies, resulting in the development of 
a local inflammatory process, which is common in the appear-
ance of psoriasis and atherosclerotic lesions [49, 50]. Increased 
expression of FRA-1 can also lead to an increase in the ex-
pression of IL-18, which induces transcription and expres-
sion of MMP9 (matrix metalloproteinase 9) and stimulates 
production of the active form MMP9. this stimulation leads 
to an increase in smooth muscles cell migration, which is an 
important part of the appearance of atherosclerotic plaques 
[51]. therefore, we can conclude that it is possible that FRA-
1 plays a crucial role in the pathogenesis of psoriasis and 
atherosclerosis. 
therefore, with the help of the bioinformatic analysis, the 
psoriatic gene networks were examined to detect the pres-
ence of relatively closed processes, and the main genes were 
identified: the regulators of the transcription complex AP-
1. transcription profiling of selected genes (C-JUN, JUNB, 
JUND, C-FOS, FRA-1 and FRA-2) based on rnA of 6 chosen 
genes showed a multidirectional regulation of these genes in 
psoriasis (data not shown). Gene FRA-1 stands out from the 
other genes analyzed that code the proteins of AP-1 complex 
(shown on Figure 5).  Moreover, change in the expression of 
this gene before and after treatment showed a clear tendency 
toward a lowering of the levels of mrnA of this gene, which 
correlated with the positive dynamic in the patients’ illness 
history (data not shown). therefore, the transcription activ-
ity of FRA-1 gene complex AP-1 may be a sort of efficiency 
indicator of treatment at the molecular level. 
PROTEOMIC STuDy
the final goal of our study was to analyze the changes oc-
curring in the metabolic pathways which lead to the patho-
geneses, since on that level we can identify new targets for 
medical treatment and new approaches to pharmacological 
therapy can be found.
With the help of the proteomic analysis of psoriatic skin 
samples, we were able to establish 10 protein markers present 
only in the psoriasis-affected skin samples but absent in the 
unaffected skin samples (table 3) [52]. A few protein families 
were of the biggest interest.
the S100 family includes at least 13 proteins, and the 
genes that code them are localized in cluster form on the 1st 
chromosome (1q21), which correlates to the psoriasis suscep-
tibility locuse PSOrS4. It is known that this protein is highly 
expressed in the psoriasis-affected skin; however, today this 
gene is no longer considered a candidate for the development 
of psoriatic processes. At this point, the exact role of this pro-
tein remains unknown.
Proteins SccA1 and SccA2 belong to the family of ser-
ine proteinase inhibitors. Some studies [53] have shown that 
protein SccA1 is expressed in the normal skin, while in the 
psoriasis affected skin its expression is twice higher. 
Protein SccA2 is not expressed in the control samples, and 
in the psoriasis-affected skin samples its expression levels are 
similar to that of SccA1. 
these proteins can be considered as potential targets for 
the pharmacological compounds in psoriasis treatment [54].
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Fig.5. Level of expression alteration of FRA-1 in affected psoriatic skin 
relative to the visually unaffected skin of the same patients (1- absence 
of expression alteration; <1 – decrease in expression in affected sample; 
>1 – increase in expression in affected sample)
Fig. 6. Level of expression alteration of FRA-1 gene in atherosclerosis 
affected vassels compared to visually unaffected (A1-A8) and psoriasis 
affected skin compared to unaffected (P1-P10). 1- absence of expres-
sion alteration; <1 – decrease of expression in affected sample; >1 – 
increase of expression in affected sample)132 | ActA nAturAe |  № 3 2009
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COMPARATIVE ANALySIS OF PSORIASIS AND 
CROHN’S DISEASE PATHOGENESIS
A multidimensional study of the molecular mechanisms of 
psoriatic pathogenesis can be considered as a model for the 
study of the pathogenesis of other immune-mediated in-
flammatory diseases (IMID – Immune-mediated inflam-
matory disorders), which are characterized by acute and 
chronic inflammatory conditions. the most common IMID-
phenotypes are crohn’s disease, ankylosing spondylitis, 
rheumatoid arthritis, psoriasis, uveitis, and psoriatic arthri-
tis. the central role in all of these diseases is played by the 
cytotoxin tnF-α (tumor necrosis factor - alpha). Figure 7 
shows the localization of gene groups responsible for the de-
velopment of these diseases [55]. crohn’s disease and ulcera-
tive colitis are chronic inflammatory diseases that are gen-
erally called IBD (inflammatory bowel disease). Both twin 
studies and the generally higher incidence of these diseases 
in close relatives point to a genetic basis for these diseases. 
the increase in the number of cases in europe and north 
America since the second half of the 20th century is an in-
dication of the strong influence of environmental factors, 
with relatively low levels of concordance in the monozygotic 
twins (~50% for the crohn’s disease and 10% for the ulcera-
tive colitis). even though animal studies do provide clues 
about the etiology of crohn’s disease, its nature  remains a 
mystery [55, 56]. 
the most whidespread hypothesis about IBD pathogen-
esis is the presence of a heavy t-cell immune response to 
certain environmental factors and some pathogenic entero-
bacteria in the genetically susceptible individuals, which 
increases the beginning or reactivation of the disease. Fig-
ure 8 shows the activation of four independent components, 
the interaction of which at different points of the disease’s 
Table 3. Proteins identified as different at involved and uninvolved psoriatic skin [52]
Blot, number Protein name
%Vol
Affected skin unaffected skin
1
Keratin 17
1.97 ± 0.92 0.18 ± 0.06 Keratin 14
Keratin 16
2 SccA2/SccA1 0.28 ± 0.09 0.066 ± 0.02
3 Squamous cell carcinoma antigen; Scc antigen 0.35 ± 0.18 0.03 ± 0.01
4 enolase 1 0.87 ± 0.22 0.40 ± 0.14
5 Superoxide dismutase [Mn] 0.22 ± 0.03 0.11 ± 0.02
6 Galectin 7; Gal – 7  1.14 ± 0.41 0.19 ± 0.01
7 Protein S100 – A9 0.54 ± 0.03 0
8 Protein S 100 – A9 0.15 ± 0.07 0
9 Protein S100-A7 (Psoriasin) 0.51 ± 0.16 0
10 Protein S100-A7 (Psoriasin) 1.36 ± 0.37 0.02 ± 0.03
Crohn disease
Sarcoidosis
Psoriasis
Atopic eczema
Astma
Periodontitis
Psoriatic arthritis
1      2     3     4      5      6       7     8     9     10     11     12
13  14  15  16  17  18  19  20  21  22
Fig.7. Clustering of linkage regions and disease genes in human inflam-
matory barrier disease [55]
Fig.8. The interaction of different factors (genetic susceptibility, envi-
ronmental triggers, luminal microbial antigens and adjuvants, immune 
response) that cause chronic-inflammation intestine process[56]reSeArcH ArtIcLeS
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development is necessary for its clinical implications. From 
our point of view, comparable studies of the genetic fac-
tors involved in the pathogenic pathways of psoriasis and 
crohn’s disease can play a significant role in the deciphering 
of the molecular mechanisms of the pathogenesis of these 
diseases.  A comparative bioinformatics analysis of microar-
ray database GeO Data Sets allowed to prepare a general 
list of the genes that undergo changes in the cell processes 
of both diseases. 
IDENTIFICATION OF GENES THAT CHANGE THEIR ExPRESSION 
IN BOTH PATHOLOGIES – PSORIASIS AND CROHN’S DISEASE
Our research was focused on the identification of differential-
ly expressed genes in each data set and comparison of these 
lists of genes at the systemic level. the approach we took in 
working on this problem was dictated by the character of the 
expression data (high noise level, large amount of data to be 
analyzed) and the attributes of each individual data set taken 
for the analysis (they were done on different types of micro-
arrays that have different numbers of probes and, therefore, 
cannot be compared directly) [57].
Originally, psoriasis data sets contained information on 
the expression of 12,626 probes for 8 experiments (4 sam-
ples of damaged skin and 4 samples of healthy skin). When 
probes with badly detectable expression were thrown out, 
the number of probes was reduced to 5,076. the list of probes 
with statistically significant differences in expression be-
tween the affected and unaffected skin samples contained 
410 probes with a significance level of 0.1.
the data sets for Crohn’s disease contained information 
on expression levels for 24,016 probes in 21 experiments (10 
intestinal epithelial samples of healthy individuals and 11 epi-
thelial samples of damaged epethilia). the list of probes with 
statistically significant differences in expression between the 
damaged and undamaged tissues was 3,850 probes, with a 
significance level of 0.1.  Such a huge difference in the probe 
lists’ sizes was due to the fact that the algorithm to control 
type I errors (FDr) depends on the size of the input set: the 
larger the number of genes in the input set, the larger the 
number of genes taken with the same p-value distribution 
that will go through FDr control. In our study, the number of 
analyzed probes in the crohn’s disease data set is five times 
that of the psoriasis data.
the resulting data sets of differentially expressed genes 
were introduced into the Metacore®.   Since microarrays 
contain not only probes for the genes studied, but also for a 
large number of eSt with unclear roles, in this step the size 
of the genes lists changed because not all of the probes have 
a correlating gene in the Metacore® database, and because 
some probes correlate to more than one gene. the size of the 
genes lists changed to 425 genes for psoriasis and 2,033 for 
crohn’s disease. 
these genes lists had 49 common genes, and the level  of 
similarity  is rather significant (p-value = 4.94x10-2).  Fisher’s 
Table 4. The list of genes common for pathogenesis of psoriasis and Crohn’s disease.
Gene Identification number Location Gene Identification number Location
GnA15 2769 19p13.3 cBX3 11335 7p15.2
GPM6B 2824 Xp22.2 uGt1A6 54578 2q37
IFI44 10561 1p31.1 DeGS1 8560 1q42.11
OAS2 4939 12q24.2 PSMe2 5721 14q11.2
FOXc1 2296 6p25 trAK2 66008 2q33
ZnF207 7756 17q11.2 DnAJc7 7266 17q11.2
IFI35 3430 17q21 cSnK1D 1453 17q25
StAt3 6774 17q21.31 trIM22 10346 11p15
tXnDc1 81542 14q22.1 IrF9 10379 14q11.2
MrPL9 65005 1q21 uBe2L6 9246 11q12
cASP4 837 11q22.2-q22.3 etS2 2114 21q22.2
MecP2 4204 Xq28 QPct 25797 2p22.2
LOnrF1 91694 8p23.1 SFPQ 6421 1p34.3
cG018 90634 13q12-q13 uGt1A4 54657 2q37
VKOrc1 79001 16p11.2 H2AFY 9555 5q31.3-q32
MIB1 57534 18q11.2 HMGn1 3150 21q22.2
rFK 55312 9q21.13 ctSc 1075 11q14.1-q14.3
SOStDc1 25928 7p21.1 SerPInB5 5268 18q21.3
KIAA1033 23325 12q24.11 Ier2 9592 19p13.13
SYncrIP 10492 6q14-q15 S100A8 6279 1q21
rArG 5916 12q13 ArMet 7873 3p21.1
DDOSt 1650 1p36.1 FGFr2 2263 10q26
cDc42eP1 11135 22q13.1 rBPMS 11030 8p12-p11
S100A9 6280 1q21 JunB 3726 19p13.2
PHGDH 26227 1p12134 | ActA nAturAe |  № 3 2009
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test was used to grade this significance; 9,017 genes present 
in the two study data sets were taken. Identification of these 
genes was done by comparing the genes lists for both gene 
microarray sets in Metacore®.
Forty-nine genes were selected for the further analysis 
and are shown in table 4. the cell molecular-genetic processes 
associated with the genes common to psoriasis and crohn’s 
disease were of a particular interest. Program methods in 
Metacore® were used to create table 5, where the most pos-
sible cell processes involving genes from table 4 are shown. 
the processes shown in table 5 can be divided into two cat-
egories: those participating in inflammation processes and 
those participating in the regulation of the cell cycle. In both 
psoriasis and crohn’s disease, the main pathological focus lies 
in the focus of inflammation. cell cycle and apoptosis are dis-
turbed in psoriasis. Keratinocytes in the focus of the inflam-
mation have no time to apoptose due to extra proliferation; 
thus, they form the skin patches we observe in psoriasis. Sim-
ilar processes take place in the intestine of crohn’s disease’s 
patients. 
REASONABLE APPROACHES TO THE PHARMACOLOGICAL 
TREATMENT OF PSORIASIS AND POSSIBLE NEW 
APPROACHES TO THE TREATMENT OF IMMuNE-
MEDIATED INFLAMMATORy ILLNESSES
Psoriasis is considered a recurrent incurable illness; its treat-
ment focuses on lengthening the remission periods and reduc-
ing the severity of the disease. the drugs used (cyclosporine, 
system retinoids and fumarates) lead only to a temporary im-
provement of the patient’s condition. nonetheless, some new 
approaches are being explored. new therapeutic methods 
are characterized by a more specific influence on the specific 
molecular targets that play a key role in the formation of the 
pathological processes in psoriasis. they include modificators 
of the biological response, such as alefacept, efalizumab, etar-
necept, infliksimab, and adalimumab, which specifically tar-
get the molecular mediators involved in the immune-patho-
genesis of psoriasis (receptors and ligands). For example, the 
suppression of tnFα activity, a key cytokine in the innate 
immune response, is achieved through three inhibitors of 
tnFα (alefacept, etarnecept, and infliksimab). etarnecept is 
a two-component protein produced from the ligand-binding 
fragment receptor tnF attached to the Fc-fragment IgG1. It 
binds tnF and blocks its interaction with cell–surface recep-
tors, reducing the inflammation process. Infliksimab – tnFα 
human monoclonal antibodies lower the activity of tnFα, 
which lowers the production of IL-1 and IL-6 [58]. therefore, 
the new generation of biological approaches to the treatment 
of psoriasis focus on the specific destruction of targets for the 
t-cell mediated pathogenic processes. 
A number of successful attempts at psoriatic arthritis 
treatment with bio-modificators have been documented since 
2001 [58, Abstract book of third eAD International Spring 
Symposium, Sofia, 2005]. tnFα levels are increased in the 
intestinal mucosa during crohn’s disease; therefore, tnFα 
inhibitors are used to treat this disease. this kind of mono-
therapy by means of bio-modificators is used for the treat-
ment of psoriatic arthritis and rheumatoid arthritis [59, 60]. 
However, a number of unusual side effects associated with 
this treatment have been reported. For example, some re-
seachers have indicated the development of psoriatic lesions 
on the skin of some crohn’s disease patients [60, 61, 62].  the 
mechanisms leading to such serious side effects are unclear; 
therefore, continued research in this area on the molecular–
genetic level is necessary.
In conclusion, the main goal of investigations of the path-
ways leading to the pathogenesis of immune–mediated dis-
eases on the molecular level is to find new pharmacological 
treatment options. the proteomic studies of skin samples 
affected by psoriasis and intestinal fragments affected by 
crohn’s disease performed by our research group are geared 
toward finding new targets for pharmacological treatment 
options. It is also necessary to compare the obtained data with 
the results of the meta-analysis of development pathways 
for these two immune-mediated inflammatory diseases done 
by us.
We used psoriasis as an example to show the necessity of 
an integrated approach to the deciphering of the disease’s 
pathogenesis stages, including clinical and bioinformatical 
analysis, as well as analysis of metabolic and genetic data, 
which will assist in the development of simple methods of 
individual characterization of pathogenesis and finding more 
effective methods for the treatment of each individual. In 
this manner, psoriasis is taken as a typical complicated dis-
order and is considered an adequate model for the study of 
the pathogenicity mechanisms for other disorders similar to 
psoriasis in their influence on human life. 
The work was supported by the Russian Federal Agency  
for Science and Innovation (federal contract 02.512.11.2231) 
and the Presidium of Russian Academy of Sciences, as a part 
of the program "Fundamental Medical Science."
Table 5. The common cell processes typical for psoriasis and Crohn’s 
disease
Processes P-value
Inflammation: interferon signaling pathway 2.19e-03
Signal transmission: Wnt signaling pathway 1.20e-02
regulation of translation initiation 5.66e-02
Morphogenesis of blood vessels 9.76e-02
DnA repair 1.17e-01
Inflammation: amphoterine signaling pathway 1.19e-01
cell cycle and apoptosis driven proteolysis 1.29e-01
Interleukin regulation of cell cycle in G1-S phase 1.29e-01
Signal transmission: androgen receptor signaling pathways 1.34e-01reSeArcH ArtIcLeS
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